

HEADING FOR NEW SHORES

How to move smoothly and quickly into Asian markets — Biopharmaceutical companies looking to manufacture in the Middle East or India may find they can't simply transfer the plant they've been using successfully in Europe, for logistic as well as regulatory reasons. An expert in integrated process technology and engineering, Glatt Ingenieurtechnik outlines the potential pitfalls and solutions.

DIRK STEINHÄUSER*


Transferring production of any pharmaceutical that contains biotechnologically produced active ingredients such as insulin, vaccines or antibodies using micro-organisms to a new country—especially one on a different continent—creates a number of challenges. Not only do tech-

nical documentation and technology have to be considered, but regulatory guidelines, which vary from country to country, and compliance issues must be addressed. The technology and engineering experts at German company Glatt Ingenieurtechnik know how to tackle these issues and have

helped several companies to set up manufacturing facilities successfully and smoothly across the Middle East and India.

* The author is deputy branch manager and sales manager at Glatt Ingenieurtechnik, Dresden/Germany.
Contact: Phone +49-351-2584850

Holistic engineering from Glatt's point of view: a three-dimensional CAD model of a fermentation plant in the Middle East.



For many pharmaceutical projects, early availability is important and fast time-to-market are imperative for the manufacturer. Effective project management and scheduling are therefore crucial. Working to a clearly defined structure based on sound experience, when it receives an initial enquiry from a pharmaceutical manufacturer, Glatt asks two fundamental questions: Does a suitable biotechnological production process already exist within the company? Or will it need to be purchased from a technology provider or licensor? As soon as these points are clarified, the Glatt engineering team will begin to evaluate and compare the relevant technologies, in line with the pharma company's specific criteria.

It is important that a defined and stable micro-organism or a high yield cell line exists, and that the scale and status of the biotechnological process has been assessed to attain regulatory approval for the pharmaceutical production in the Middle East, in India or other process technology receiving regions. If the procedure only exists in a laboratory, scale-up may be available at a pilot plant or—better still—a proven and commercial-scale process may have already been established at a potential process technology donor location.

This status report determines the schedule of the entire project. Additional evaluation criteria include, among other things, secured patent status, any royalties to be paid, material requirements, expected turnover rate and yield. It is also important to know whether guarantees can be given regarding process parameters such as yield and product purity.

The right choice

The next milestone is technology comparison, which will result in the selection of preferred technology candidates. Subsequent negotiations will hopefully lead to a Tech Transfer Agreement (TTA); and, with the signed TTA or a li-

cence agreement in place, the technology provider will hand over the planning input. Alongside a process description, characteristic flow diagrams, quality and measurement parameters and Standard Operating Procedures (SOPs) from reference systems should also be available.

Local authority requirements for the approval of the technology required to manufacture the products must also be considered. For instance, the reference authority for all Arabian Gulf Co-operation Council (GCC) countries is the Saudi Food and Drug Authority (SFDA), which is oriented towards biopharmaceutical products at the European EMA.

It is therefore advisable for the manufacturer to define their specific requirements or design basis documents clearly. General requirements such as “all our operational standards must be taken into account as well as the company standards of the licensor” simply lead to duplication and don't necessarily fit the project and this can sometimes render a clear design solution impossible. By comparing Tech Transfer Packages and applied practices, user requirements and SOPs can often be used as a future design base for projects in countries with similar requirements.

Cross-country partnerships

Biopharmaceutical projects in Asia and the Middle East are under pressure from Indian manufacturers with low-cost production capabilities. Thus, when procuring equipment components, it is vital to conduct a global search and to source the most cost-effective solution. Finding a partner who can assist with both engineering and technology transfer is also crucial.

GMP reviews regarding process planning, zoning and layout should be conducted at an early stage—during the concept phase. They should involve the technology providers, the engineering service team and the future operator.



Source: Julphar

Training staff early on helped Julphar Gulf Pharmaceuticals to achieve speedy commissioning and operation start at its new biotech plant in the UAE.

Regular design review meetings are also essential. A previous project, for example, involved several meetings between a biotech company from the Arab GCC region and technology licensors from the United States at the Glatt engineering offices in Germany. Part of the technology transfer involved increasing the scale of production, so Glatt's biotech team conducted a series of tests with appropriate equipment manufacturers. The results of the multi-week trials were included in the project plan, as were the additional transport, time and costs involved.

To reduce production costs, it is important to involve regional specialist planners and suppliers. Another crucial project in best cost countries is to procure equipment components. Glatt Engineering's procurement strategy remains independent of its own portfolio of equipment, and takes into account the best manufacturers, suppliers, references and fulfilment requirements for the task in question.

It is Glatt's policy to ensure that key staff from the client company is given a proper training at the Licensors plant in Europe to prepare for technology transfer. In all cases, Glatt's biotechnologists recommend early sourcing of key staff, joint training with the technology provider and the engineering team. This way, and by expanding the team in a step-by-step manner, full operational efficiency can be achieved more quickly than might be imagined.

PROCESS-Tip

• Save the date: Meet the Engineering experts of Glatt Ingenieurtechnik at **Achema** in Frankfurt, June 11–15, 2018: hall 3.0, stand F1